|
|
|
| home > ebr > Winter 2009 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR |
 |
| |
|
|
|
| Independent consultant Emile Bellott looks at the changing biotech
landscape in light of the global financial crisis and considers the
likely implications for the global pharmaceutical/biotech industry |
|
|
| Mark B Hassenplug and Kai Gindner at Ernst & Young examine ways in which
pharmaceutical companies can maintain standards in supply chain management |
|
|
|
| Pharma and biotech companies often manage scientific assets and equipment on their own. Bob Moore at GE
Healthcare discusses why and how outsourcing scientific asset services can help to improve effectiveness in the lab |
|
|
| Catherine D’Arcy at PA Consulting Group describes the requirement for greater
efficiency and effectiveness in R&D operations and how working closely with
a global pharmaceutical company has prompted a review of key functions |
|
|
| Richard Barratt at Barratt Legal examines the proliferation of outsourcing
operational practices in the industry, and tells us how to get the best out of it |
|
|
|
| Mats Hellström and Björn Frendéus at BioInvent International examine the developments that
are occurring in monoclonal antibody drugs, and discuss their future in the fight against cancer |
|
|
| Birgit Jehn at QIAGEN GmbH gives an overview on HLA-Typing
or pre-therapeutic testing in AIDS patients |
|
|
|
|
| David Bunton and Lee Rankin at Biopta Ltd and Alistair Corbett at Glasgow
Caledonian University discuss opioid receptors as drug targets in gastrointestinal disorders |
|
|
| Graham Lappin at Xceleron argues that microdosing can provide important information about
a drug’s behaviour before Phase I, thereby reducing the likelihood of costly failures at a later stage |
|
|
|
| Ulrich Braumann at Bruker BioSpin and Herbert Thiele at Bruker Daltonik analyse
structure verification of small molecules using integrated MS spectrometry and NMR spectroscopy |
|
|
| Josep Prous at Thomson Reuters introduces biomarkers, identifying them
as a crucial factor in the evolution of drug research and development |
|
|
| LABALisette
Oversteegen at Datamonitor discusses combination
product market trends in the respiratory drug sector |
|
|
|
| R Keith Williams at The Clinical Biotechnology Centre, Bristol Institute for Transfusion Sciences, NHS Blood and Transplant and Angela Osborne of eXmoor pharma concepts ltd discuss small-scale biomanufacturing for clinical trials, cell and gene therapies in the UK market |
|
|
| Kate Westwell and Gina Wenham at Eden Biodesign explain
how implementing the quality cycle can deliver product value |
|
|
|
| Jacques Lhomel of Biocitech tells how one of Europe’s high-profile
life science parks has boosted resources for life sciences R&D |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Clinical and Regulatory Operational Excellence Forum
1. Innovative technologies are expected to take clinical development, licensing, and other regulatory processes to the next level in the future. What do you see are the biggest challenges facing companies when trying to cope with continued data growth in a fast changing environment?
Pharmaceutical companies are heavily regulated and introducing change needs proof of acceptance by the authorities. The chance that authorities do not agree with that change makes the industry risk averse. Changes in a stable GxP environment are almost by default seen as a risk, however, not adapting to new technologies should also be seen as a risk! Therefore, ICH developed the ICH Q8, Q9, Q10, Q11, and Q12 guidelines, to anticipate change and implement changes much faster, with less of a regulatory burden. Nevertheless, industry is not picking up with the desired pace. Why not?
More info >> |
|
 |
White Papers |
 |
|
 |
Industry Events |
 |
CPhI & P-MEC India 2018
12-14 December 2018, India Expo Mart, New Delhi, India
CPhI & P-MEC India (December 12-14, 2018) – organised by UBM (part
of Informa PLC) – announces that the 12th edition of Asia’s
largest Pharma exhibition is moving to the India Expo Mart, New Delhi. The new
venue will see the exhibition now hosted in a single venue, bringing it closer
to the Indian regulatory and legislative capital. New Delhi is also the
country’s main international transport hub and will encourage an increased
international attendance. In total, more than 50,000 people from 122 countries
are expected, along with nearly 1,500 exhibitors.
More info >> |
|
|
